FDA accepted Apnimed's NDA for AD109, an oral treatment for adults with obstructive sleep apnea.
What this means
AD109 is an oral drug designed to treat obstructive sleep apnea by targeting the muscles in the upper airway to keep them from collapsing during sleep. The FDA has accepted Apnimed's application to review AD109 for this condition, starting its formal evaluation. If approved, it could offer a new, non-invasive pill option for a disorder that currently often requires bulky nighttime machines or surgery.
